Comparative Pharmacology
Head-to-head clinical analysis: MIRCERA versus RETACRIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRCERA versus RETACRIT.
MIRCERA vs RETACRIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MIRCERA (methoxy polyethylene glycol-epoetin beta) is a continuous erythropoietin receptor activator that stimulates erythropoiesis by binding to and activating the erythropoietin receptor, leading to increased red blood cell production.
RETACRIT (epoetin alfa-epbx) is a recombinant human erythropoietin that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation into mature red blood cells.
Initial dose 0.6 mcg/kg intravenously or subcutaneously every 2 weeks; for patients not on dialysis, initial dose 1.2 mcg/kg subcutaneously every 2 weeks; target hemoglobin 10-12 g/dL.
50-100 IU/kg intravenously or subcutaneously three times weekly; initial dose 50 IU/kg three times weekly, titrated to target hemoglobin 10-12 g/dL.
None Documented
None Documented
Terminal half-life approximately 130-140 hours (about 5-6 days) in patients with chronic kidney disease. This long half-life supports once-monthly dosing. In healthy volunteers, half-life is about 134 hours.
Terminal elimination half-life is ~2.5-4.5 hours following intravenous administration; shorter in children; prolonged in hepatic impairment.
Renal (minimal, as MIRCERA is a large glycoprotein that is not significantly filtered by the glomerulus). The majority is eliminated via binding to EPO receptors on target cells followed by internalization and degradation, with less than 10% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Primarily hepatic metabolism; ~10% excreted unchanged in urine, remainder via feces as metabolites.
Category C
Category C
Erythropoiesis-Stimulating Agent
Erythropoiesis-Stimulating Agent